Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 1/2014

01-08-2014 | Erratum

Erratum to: Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas

Authors: Kathleen Dorris, Matthew Sobo, Arzu Onar-Thomas, Eshini Panditharatna, Charles B. Stevenson, Sharon L. Gardner, Mariko D. DeWire, Christopher R. Pierson, Randal Olshefski, Sandra A. Rempel, Stewart Goldman, Lili Miles, Maryam Fouladi, Rachid Drissi

Published in: Journal of Neuro-Oncology | Issue 1/2014

Login to get access

Excerpt

In Table 2 of the original publication, the data in table columns 6–13 were incorrectly displayed for the table rows of IDs 37, 45–47. The correct data are shown in bold below.
Table 2
Summary of clinical characteristics and telomere maintenance assay results
ID
Gender
Age (years)
Tumor
Pathology
Specimen Timing
Resection
Telomerase activity by TRAP
ALT
TERT (RQ)
TERC (RQ)
Time to death or last follow-up (years)
Deceased
1
M
8.8
DIPG
GBM
A
N/A
–
+
5.38
8.56
0.84
Y
2
F
12.1
DIPG
AA
D
Partial
N/A
N/A
52.29
1.46
2.26
Y
3
F
22.2
HGG
GBM
D
Partial
–
+
0
0.31
1.53
N
4
F
12.0
DIPG
AA
A
N/A
–
+
0.50
5.03
1.21
Y
5
F
10.2
HGG
AA
D
Partial
–
+
0.11
0.23
11.19
N
6
F
17.9
HGG
GBM
R
Partial
N/A
N/A
0.49
1.58
3.47
Y
7
M
17.9
HGG
AA
D
Partial
+
N/A
80.21
1.40
1.18
Y
8
F
2.5
HGG
AA
D
Total
–
N/A
0
4.031
5.36
N
9#
M
17.9
HGG
AA
D
Partial
–
+
0
0.84
2.98
Y
10#
M
17.9
HGG
GBM
R
Partial
+
+
4.058
0.32
2.98
Y
11
M
5.9
HGG
GBM
D
Partial
N/A
N/A
0.44
1.70
2
N
12
M
13.8
HGG
AA
D
Total
N/A
N/A
0.36
1.18
0.27
N
13
M
12.1
HGG
GBM
D
Total
N/A
N/A
0
0.43
3.23
N
14
M
3.7
HGG
AA
D
Partial
–
N/A
0.14
0.21
0.26
N
15*
M
12.1
HGG
GBM
R
Total
N/A
N/A
57.91
5.29
3.23
N
16*
M
12.1
HGG
GBM
R
Total
N/A
N/A
71.41
1.73
3.23
N
17^
F
0.02
HGG
GBM
R
Partial
–
N/A
N/A
N/A
21.38
N
21
F
5.1
DIPG
GBM
A
N/A
–
N/A
3.58
5.22
1.16
Y
22
F
3.2
DIPG
AA
A
N/A
N/A
N/A
5.44
26.016
0.56
Y
23
M
5.4
DIPG
GBM
A
N/A
+
–
6.37
2.47
0.68
Y
24
F
12.5
DIPG
GBM
A
N/A
+
–
4.83
6.40
0.81
Y
25
F
12.1
DIPG
GBM
A
N/A
N/A
N/A
0.80
2.38
0.78
Y
26
M
2.8
DIPG
GBM
A
N/A
–
–
1.68
2.45
2.64
Y
27
F
3.4
DIPG
GBM
A
N/A
–
–
0.12
0.53
0.42
Y
36
F
4.7
DIPG
GBM
A
N/A
–
–
9.027
2.65
1.58
Y
37
F
4.8
DIPG
GBM
A
N/A
–
–
3.92
5.82
1.25
Y
45
F
9.6
DIPG
GBM
A
N/A
–
+
15.22
5.92
0.64
Y
46
F
4.2
DIPG
GBM
A
N/A
–
–
0.14
0.84
0.81
Y
47
F
4.6
DIPG
GBM
A
N/A
+
–
7.12
2.85
1.95
Y
28
F
6.9
HGG
GBM
R
Total
+
–
5.31
1.056
3.58
Y
29
F
20
HGG
GBM
R
Partial
–
+
0.33
0.18
0.83
N
30
M
6
HGG
GBM
D
Partial
–
N/A
8.45
19.36
0.08
Y
31
F
15.8
HGG
AA
D
Partial
–
–
0.30
1.44
2.25
N
32
F
13.8
HGG
GBM
D
Total
+
–
499.71
0.20
1
Y
33
M
15.2
HGG
GBM
D
Partial
+
–
2.99
3.21
1.42
Y
34
F
7.4
HGG
AA
D
Partial
–
+
0
3.13
1.58
Y
35
M
15.2
HGG
GBM
D
Total
+
–
15.46
0.15
3
N
38
M
17.8
HGG
AA
R
Partial
–
+
0.087
0.62
1.5
N
39+
M
19.2
HGG
GBM
D
Total
–
+
1.18
0.42
4.58
N
40+
M
19.2
HGG
GBM
R
Total
–
–
0.30
0.20
4.58
N
41
M
16.6
HGG
GBM
D
Partial
–
N/A
0.30
0.41
0.65
Y
42
M
8.4
HGG
GBM
D
Partial
–
–
0.23
0.76
0.8
Y
43
F
11.6
HGG
GBM
D
Partial
–
+
1.83
8.20
0.77
Y
44
M
12.4
HGG
GBM
D
Partial
+
–
19.80
0.70
1.87
Y
48
M
15
HGG
GBM
D
Total
+
–
6.65
0.84
0.91
Y
49
M
12
HGG
GBM
R
Total
–
+
4.33
0.90
2.24
Y
50
M
20
HGG
GBM
D
Total
–
–
0.37
1.12
0.45
Y
HGG non-brainstem high-grade glioma, DIPG diffuse intrinsic pontine glioma, GBM glioblastoma multiforme, AA anaplastic astrocytoma, RQ relative quantification, specimen timing, A autopsy, D diagnosis, R relapse
#, ^, *, + Serial specimens from same patient
…
Metadata
Title
Erratum to: Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas
Authors
Kathleen Dorris
Matthew Sobo
Arzu Onar-Thomas
Eshini Panditharatna
Charles B. Stevenson
Sharon L. Gardner
Mariko D. DeWire
Christopher R. Pierson
Randal Olshefski
Sandra A. Rempel
Stewart Goldman
Lili Miles
Maryam Fouladi
Rachid Drissi
Publication date
01-08-2014
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1511-5

Other articles of this Issue 1/2014

Journal of Neuro-Oncology 1/2014 Go to the issue

Clinical Study

Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma

Clinical Study

Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI

Erratum

Erratum to: Institutional charges and disparities in outpatient brain biopsies in four US States: The State Ambulatory Database (SASD)

Clinical Study

Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors

Clinical Study

The relationship between working memory and cerebral white matter volume in survivors of childhood brain tumors treated with conformal radiation therapy

Clinical Study

Elderly patients aged 65–75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide